Q4 2025 LivaNova PLC Earnings Call Transcript
Key Points
- LivaNova PLC (LIVN) achieved double-digit revenue growth for the fifth consecutive year, with strong performance in both cardiopulmonary and epilepsy segments.
- The company reported a significant improvement in adjusted operating margins and robust cash generation, reflecting effective execution of its business strategy.
- LivaNova PLC (LIVN) is advancing its long-term strategy by entering high-growth markets such as obstructive sleep apnea, supported by rigorous clinical evidence and differentiated technology.
- The company received FDA approval for its cloud-based digital health platform, establishing a foundation for connected care in epilepsy and other areas.
- LivaNova PLC (LIVN) has strengthened its leadership team with strategic appointments, enhancing its capabilities to execute its growth strategy.
- Some planned placements of the Essenz heart-lung machine shifted into 2026, moderating the fourth quarter contribution.
- The company faces third-party supply constraints in its cardiopulmonary consumables segment, impacting oxygenator output.
- LivaNova PLC (LIVN) anticipates a moderation in the price premium for its Essenz heart-lung machine, which could affect revenue growth.
- The company is experiencing increased R&D expenses, driven by investments in obstructive sleep apnea and core product development.
- There is uncertainty regarding the timing of CMS reimbursement decisions for difficult-to-treat depression, which could impact future revenue.
Good day, ladies and gentlemen, and welcome to the LivaNova PLC Fourth Quarter and Full Year 2025 Earnings Conference Call. My name is Emily, and I will be coordinating your call today. (Operator Instructions) As a remainder this conference call is being recorded.
I would now like to introduce your host for today's conference Ms. Briana Gotlin, LivaNova's Vice President of Investor Relations. Please go ahead.
Thank you, and welcome to our conference call and webcast discussing LivaNova's financial results for the fourth quarter and full year of 2025. Joining me on today's call are Vladimir Makatsaria, our Chief Executive Officer and member of the Board of Directors; Alex Shvartsburg, our Chief Financial Officer; Ahmet Tezel, our Chief Innovation Officer; and Zach Glazier, Director of Investor Relations.
Before we begin, I would like to remind you that the discussion during this call will include forward-looking statements. Factors that could cause actual results to differ
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
